| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The functional target is cytochrome P450 1A1 (CYP1A1), with 7-ethoxyresorufin acting as a substrate in the EROD (ethoxyresorufin-O-deethylase) assay. Reported kinetic parameters for the parent substrate include Km = 0.34 ± 0.02 µM and Vmax = 95.20 ± 8.14 pmol/min/mg for human CYP1A1, and Km = 0.42 ± 0.05 µM for rat CYP1A1. The compound also has NO synthase inhibitory activity.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In the EROD assay, CYP1A1-mediated O-deethylation of 7-ethoxyresorufin-d5 releases non-deuterated resorufin (MW 213.19) from the d5-substrate (MW 246.27), a mass difference of 33.08 Da that allows LC-MS or GC-MS tracking of substrate-to-product conversion. Fluorescence detection uses excitation at 530 nm and emission at 580 nm. Because deuterium is on the leaving ethoxy group, the product is unlabeled resorufin, not a deuterated product. |
| ln Vivo |
This reagent has no intrinsic in vivo pharmacological activity. Its in vivo application is limited to analytical method development, where it serves as a stable-isotope-labeled surrogate or internal standard for quantifying 7-ethoxyresorufin and resorufin in biological matrices by LC-MS/MS. No efficacy, pharmacokinetic, or toxicological data exist for the deuterated compound as a therapeutic agent.
|
| Enzyme Assay |
For EROD assays, recombinant human CYP1A1 or hepatic microsomes are incubated with 7-ethoxyresorufin-d5 at concentrations spanning the Km (approximately 0.1–10 µM) in phosphate buffer at 37°C. The reaction is initiated with NADPH and terminated after a defined interval with methanol or acetonitrile. Resorufin formation is quantified by fluorescence (Ex 530/Em 580 nm) or by LC-MS/MS. For MS-based tracking, C18 reverse-phase chromatography with ESI positive-ion mode separates the d5-substrate (m/z corresponding to MW 246.27) from the d0-product resorufin (MW 213.19).
|
| Cell Assay |
For cell-based EROD assays, cells with inducible or constitutive CYP1A1 activity (e.g., HepG2, MCF-7, or primary hepatocytes) are seeded in black 96-well plates and treated with CYP1A1 inducers if required. Cells are then incubated with 7-ethoxyresorufin-d5 in phenol-red-free medium at 37°C for 30–60 min, and resorufin fluorescence in the supernatant is measured. For MS-based substrate-product tracking, cells are lysed or medium is extracted and analyzed by LC-MS/MS. Cytotoxicity controls are included to confirm that the assay reflects enzymatic activity rather than cell loss.
|
| Animal Protocol |
No animal protocol is established for the deuterated compound as a pharmacological agent. For analytical validation, 7-ethoxyresorufin-d5 can be spiked into plasma, liver homogenate, or microsomal incubations as an internal standard, and its recovery, matrix effect, and stability are assessed by LC-MS/MS. In vivo studies using the non-deuterated parent compound in CYP1A1 induction models can be supported analytically with the d5 standard, but the labeled compound itself is not administered for efficacy endpoints.
|
| References |
|
| Molecular Formula |
C14H11NO3
|
|---|---|
| Molecular Weight |
241.242043733597
|
| Exact Mass |
246.105
|
| CAS # |
2749329-28-8
|
| Related CAS # |
7-Ethoxyresorufin;5725-91-7
|
| PubChem CID |
163322595
|
| Appearance |
Orange to red solid
|
| LogP |
1.8
|
| tPSA |
47.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
450
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C([2H])([2H])OC1=CC2=C(C=C1)N=C3C=CC(=O)C=C3O2
|
| InChi Key |
CRCWUBLTFGOMDD-ZBJDZAJPSA-N
|
| InChi Code |
InChI=1S/C14H11NO3/c1-2-17-10-4-6-12-14(8-10)18-13-7-9(16)3-5-11(13)15-12/h3-8H,2H2,1H3/i1D3,2D2
|
| Chemical Name |
7-(1,1,2,2,2-pentadeuterioethoxy)phenoxazin-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1452 mL | 20.7262 mL | 41.4525 mL | |
| 5 mM | 0.8290 mL | 4.1452 mL | 8.2905 mL | |
| 10 mM | 0.4145 mL | 2.0726 mL | 4.1452 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.